We are live on ! Find out more
GHRS icon

GH Research

34 hedge funds and large institutions have $352M invested in GH Research in 2023 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more funds holding in top 10

Funds holding in top 10: 13 (+2)

48% more capital invested

Capital invested by funds: $237M → $352M (+$114M)

17% more funds holding

Funds holding: 2934 (+5)

0% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 8

0.11% less ownership

Funds ownership: 57.08%56.97% (-0.11%)

Holders
34
Holders Change
+5
Holders Change %
+17.24%
% of All Funds
0.53%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.05%
New
5
Increased
8
Reduced
8
Closed
Calls
Puts
Net Calls
Net Calls Change

GHRS Hedge Fund Activity: Q2 2023 in Review

34 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in GH Research (GHRS) for Q2 2023, worth a combined $352M — up 48% from $237M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new GHRS positions and 0 closed out — a net gain of 5 holders — while 8 added to existing stakes and 8 trimmed.

The largest buyer was Lynx1 Capital Management, opening a new position worth an estimated $9.94M. The largest seller was OrbiMed, cutting an estimated $9.46M.

  • 34 institutional investors held GH Research (GHRS) as of Q2 2023, up from 29 in Q1 2023.
  • Funds reported $352M of GH Research stock for Q2 2023, up 48% quarter-over-quarter.
  • 5 funds opened new GH Research positions in Q2 2023 and 0 closed out, a net change of +5 holders.
  • The largest GH Research buyer in Q2 2023 was Lynx1 Capital Management, an estimated $9.94M added.
  • The largest GH Research seller in Q2 2023 was OrbiMed, an estimated $9.46M sold.

Based on aggregated 13F filings for Q2 2023.